EP3351246

NOVARTIS AG
Application Number
EP18155644A
Filing Date
Feb 18, 2002
Status
Revoked
Oct 23, 2023
Grant Date
Sep 18, 2019
External Links
Slate, Register

Biblio Summary

The patent EP3351246B8 was granted on Sep 18, 2019 by Novartis Ag The patent is currently Revoked.

The table below shows 9 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ARROW GENERIQUESFeb 24, 2020ADMISSIBLE
TEVAFeb 22, 2020ADMISSIBLE
GENERICS UKFeb 21, 2020ADMISSIBLE
DR. REDDY'S LABORATORIES LTD./ BETAPHARM ARZNEIMITTEL GMBHJan 29, 2020ADMISSIBLE
ZENTIVA PHARMA GMBHSep 16, 2019ADMISSIBLE
ACCORD HEALTHCARE LTDJul 31, 2019WITHDRAWN
ETHYPHARMJul 3, 2019ADMISSIBLE
BIOGARANJul 1, 2019ADMISSIBLE
STADAMay 23, 2019ADMISSIBLE

The table below shows the patents of Novartis Ag that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3124018Oral Formulations Of DeferasiroxApr 24, 20242
EP4159204Novel Pharmaceutical CompositionFeb 14, 20244
EP4159205Novel Pharmaceutical CompositionFeb 14, 20245